华法林抗凝治疗用药监护研究进展

Research progress of drug-use monitoring of warfarin anticoagulant

华法林是传统抗凝药物,有60余年临床治疗史,药理作用、不良反应和各项注意事项明确,在很长一个时期仍是临床抗凝治疗主要药物。在我国,抗凝治疗率还比较低,主要原因是对缺血性栓塞风险认识不足以及对出血风险过于担忧且缺乏对抗凝治疗患者的有效管理方法。有必要提高医生和患者对栓塞风险的认识及主动抗凝意识,加强对抗凝治疗患者的有效管理,改善房颤等栓塞高风险人群生活质量。

Warfarin is a traditional medicine for anticoagulant therapy. Warfarin has been used for more than 60 years in clinical treatment. The pharmacological effects and adverse reactions of warfarin are clear,and it has still been for a long time the main drug for clinical anticoagulant therapy. In China,anticoagulant treatment rate is relatively low,mainly due to lack of understanding of ischemic embolism risk,too much concern about bleeding risk and effective management methods for anticoagulant therapy patients. Improving the understanding of embolization risks, improving the awareness of active anticoagulation and enhancing effective management of anticoagulant therapy are the key to improving the quality of life in patients with high risk of embolism,such as atrial fibrillation.